Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: There is significant practice variation in oral anticoagulation ( OAC ) use following catheter ablation for atrial fibrillation. It is not clear whether the risk of cardioembolism increases after discontinuation of OAC following catheter ablation. Methods and Results: We identified 6886 patients within a large national administrative claims database who underwent catheter ablation for atrial fibrillation between January 1, 2005, and September 30, 2014. We assessed the effect of time off of OAC by CHA 2 DS 2 ‐ VAS c score (after adjusting for other comorbidities) on risk of cardioembolism, using Cox proportional hazards models. There was an increase in the use of non–vitamin K OAC after ablation from 0% in 2005 to 69.8% in 2014. OAC discontinuation was high, with only 60.5% and 31.3% of patients remaining on OAC at 3 and 12 months, respectively. The rate of discontinuation was higher in low‐risk patients (82% versus 62.5% at 12 months for CHA 2 DS 2 ‐ VAS c 0–1 versus ≥2, respectively; P <0.001). Stroke occurred in 1.4% of patients with CHA 2 DS 2 ‐ VAS c ≥2 and 0.3% of those with CHA 2 DS 2 ‐ VAS c 0 or 1 over the study follow‐up. The risk of cardioembolism in the first 3 months after ablation was increased among those with any time off OAC (hazard ratio 8.06 [95% CI 1.53–42.3], P <0.05). The risk of cardioembolism beyond 3 months was increased with OAC discontinuation among high‐risk patients (hazard ratio 2.48 [95% CI 1.11–5.52], P <0.05) but not low‐risk patients. Conclusion: The overall risk of stroke in postablation patients is low; however, OAC discontinuation after ablation is common and is associated with increased risk of cardioembolism for all patients within the first 3 months and for high‐risk patients in the long term. Continuing OAC for at least 3 months in all patients and indefinitely in high‐risk patients appears to be the safest strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430 · cited 1×
“Indeed, >10 000 patients (all of whom were at least moderate risk) were required to demonstrate the noninferiority of NOACs to warfarin in randomized clinical trials.(26) Despite some observational data supportive of OAC discontinuation after ablation, current guidelines suggest continuation of OAC for a minimum of 2…”
BackgroundSelf-citationLip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056
Piccini, J. P., Hammill, B. G., Sinner, M. F., Jensen, P. N., Hernandez, A. F., Heckbert, S. R., Benjamin, E. J., & Curtis, L. H. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.962688 · Cited by 565
Self-citationVerma, A., Champagne, J., Sapp, J., Essebag, V., Novak, P., Skanes, A., Morillo, C. A., Khaykin, Y., & Birnie, D. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1561 · Cited by 315 · cited 1×
“Patients who undergo AF ablation may have other stroke risk factors that persist after ablation, and asymptomatic AF recurrences are not uncommon.(3,4) In addition, ablation may modify electrical activation of the left atrial appendage and introduce consequent mechanical dysfunction.”
BackgroundChao, T.-F., Liu, C.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Tuan, T.-C., Chen, T.-J., Lip, G. Y. H., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.11.046 · Cited by 258
Friberg, L., Skeppholm, M., & Terént, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.10.052 · Cited by 207
Rate- and Rhythm-Control Therapies in Patients With Atrial Fibrillation: A Systematic Review
Al-Khatib, S. M., Allen LaPointe, N. M., Chatterjee, R., Crowley, M. J., Dupre, M. E., Kong, D. F., Lopes, R. D., Povsic, T. J., Raju, S. S., Shah, B., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1467 · Cited by 178 · cited 1×
“Although one might expect that maintenance of sinus rhythm would lower the subsequent risk of stroke, systematic reviews of the available data do not necessarily support this notion.(2) Patients who undergo AF ablation may have other stroke risk factors that persist after ablation, and asymptomatic AF recurrences are…”
ResultLakkireddy, D., Reddy, Y. M., Di Biase, L., Vallakati, A., Mansour, M. C., Santangeli, P., Gangireddy, S., Swarup, V., Chalhoub, F., Atkins, D., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.039 · Cited by 177
Lip, G. Y. H., Skjøth, F., Rasmussen, L. H., & Larsen, T. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.044 · Cited by 171
Karasoy, D., Gislason, G. H., Hansen, J., Johannessen, A., Køber, L., Hvidtfeldt, M., Özcan, C., Torp-Pedersen, C., & Hansen, M. L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu421 · Cited by 132 · cited 1×
“Another analysis of Danish registries indicated that the bleeding risk associated with OAC beyond 3 months after ablation may outweigh the benefits of stroke risk prevention.(19) Several other smaller studies have also found that OAC can be safely discontinued after successful catheter ablation in selected patients wi…”
Background
Cited by
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Self-citationCalkins, H., Hindricks, G., Cappato, R., Kim, Y.-H., Saad, E. B., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.012 · Cited by 2,755
Self-citationOtto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000932 · Cited by 2,449
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 1,982
Metadata
- Authors
- Noseworthy, P. A., Yao, X., Deshmukh, A. J., Van Houten, H., Sangaralingham, L. R., Siontis, K. C., Piccini, J. P., Asirvatham, S. J., Friedman, P. A., Packer, D. L., Gersh, B. J., & Shah, N. D.
- Venue
- Journal of the American Heart Association
- Published
- 2015-10-29
- Volume
- 4
- Issue
- 11
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2131656089
- Cited by
- 87
- References
- 12
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.